Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN59798735

Enrollment

Registered

2007-05-01

Start date

2007-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease Nervous System Diseases Parkinson's disease

Interventions

Interventions amended as of 05/09/2007: All participants will receive celecoxib oral medication of 100 mg daily for 1 month. Interventions provided at time of registration: Celecoxib oral medicati

Eligibility

Inclusion criteria

Inclusion criteria: 1. Early Parkinson's disease patients 2. Hoehn and Yahr Parkinson's Disease Rating Scale (HY) 1 - 2

Exclusion criteria

Exclusion criteria: Gastrointestinal diseases

Design outcomes

Primary

Measure	Time frame
One baseline and one follow-up Positron Emission Tomography (PET) scan (PK11195) and one Magnetic Resonance Imaging (MRI) scan will be performed to assess the reduction of specific cerebral radiotracer uptake (volume of distribution according to Logan graphical method) after celecoxib.	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026